Loading

Investor Relations

Corporate Profile

We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus associated with various conditions.

Copyright West LLC. Minimum 15 minutes delayed.

Events

Menlo Therapeutics to Present at the HC Wainwright 21st Annual Global Investment Conference

REDWOOD CITY, Calif. , Aug. 29, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Kristine Ball , chief financial officer of Menlo Therapeutics

Menlo Therapeutics Reports Second Quarter 2019 Financial Results and Provides Program Updates Including Accelerated Timeline for Upcoming Clinical Data

Results from Serlopitant Phase 2 Clinical Trial for the Treatment of Chronic Pruritus of Unknown Origin Anticipated in Q1 2020 Results from Serlopitant Phase 3 Clinical Trials for the Treatment of Pruritus with Prurigo Nodularis Anticipated in H1 2020 REDWOOD CITY, Calif. , Aug.

Menlo Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference

REDWOOD CITY, Calif. , July 31, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta , Menlo’s Chief Executive Officer, will present at